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Target volume delineationObjective: Delineation of treatment volumes is a major source of uncertainties in radiotherapy (RT). This
is also true for rectal cancer patients undergoing neoadjuvant RT, with a potential impact on treatment
quality. We investigated the role of the digital platform Anatom-e (Anatom-e Information Sytems Ltd.,
Houston, Texas) in increasing the compliance to follow a specific treatment protocol in a multicentric set-
ting.
Materials and methods: Two clinical cases of locally advanced rectal cancer were chosen. Participants
were instructed to follow the 2009 Radiation Therapy Oncology Group consensus atlas and asked to man-
ually segment clinical target volumes (CTVs), for both patient 1 and 2, on day 1 with and without the use
of Anatom-e. After one week (day 2), the same radiation oncologist contoured again, with and without
Anatom-e, the same CT series. Intraobserver (Intra-OV) and interobserver (Inter-OV) variability were
evaluated with the Dice similarity coefficient (DSC), the Hausdorff distance (HD) and mean distance to
agreement (MDA).
Results: For clinical case 1, no significant difference was found for Intra-OV and Inter-OV. For clinical case
2, no significant difference was found for Intra-OV but a statistically significant difference was found for
Inter-OV in DSC when using or not the platform. Mean DCS was 0.65 (SD: ±0.64; range: 0.58–0.79) for day
1 vs reference volume without Anatom-e and 0.72 (SD: ±0.39; range: 0.67–0.77) (p = 0.03) with it. Mean
MDA was lower with Anatom-e (3.61; SD: ±1.33; range: 2.85–4.78) than without (4.14; SD: ±2.97; range:
2.18–5.21), with no statistical significance (p = 0.21) The use of Anatom-e decreased the SD from 2.97 to
1.33. Mean HD was lower with Anatom-e (26.06; SD: ±2.05; range: 24.08–32.62), with no statistical sig-
nificance (p = 0.14) compared to that without (31.39; SD: ±1.31; range: 26.14–48.72).observer
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34 P. Franco et al. / Clinical and Translational Radiation Oncology 11 (2018) 33–39Conclusions: The use of Anatom-e decreased the Inter-OV in the CTV delineation process for locally
advanced rectal cancer with complex disease presentation planned for neoadjuvant RT. This system
may be potentially helpful in increasing the compliance to follow shared guidelines and protocols.
 2018 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and
Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction experience in the treatment of rectal cancer was selected to partic-A multidisciplinary approach, including total mesorectal exci-
sion, radiotherapy (RT) and chemotherapy (CHT) is presently con-
sidered the standard of care for the treatment of locally advanced
rectal cancer [1,2]. Pre-operative RT is a well-established option to
provide tumor downsizing and downstaging and to increase loco-
regional control in this setting [3]. Selection and delineation of
clinical target volume (CTV) and organs at risk (OARs) are crucial
steps to deliver precise and tailored radiation [4–6]. While the sites
and subsites of irradiation are, to some extent, agreed by physi-
cians, the boundaries of CTVs still remain controversial, leading
to inhomogeneous contours and systematic errors with standard
deviations as high as 1 cm, as reported in different studies [7,8].
Generally speaking, most of the heterogeneity is due to the differ-
ence in contouring protocols used by the treating physician, but
the magnitude of this uncertainty is also related to the imaging
modalities and technical approaches used in the delineation pro-
cess [9]. In the context of pelvic malignancies, one of the major
sources of uncertainty is the lack of clearly-defined anatomical
boundaries in this region, which may lead to detectable contouring
differences among radiation oncologists [8]. From an anatomical
point of view, the site of major disagreement is to be located in
the upper anterior and inferior aspect of the mesorectum, which
is a critical structure for tumor control given the likelihood of
microscopic involvement, particularly for locally advanced cases
[7,10]. Several strategies can be implemented to reduce this source
of error, including periodic training for radiation oncologists, the
use of shared delineation guidelines, and quality assurance pro-
cesses with online platform for centralized revision [11].
Anatom-e (Anatom-e Information Sytems Ltd., Houston, Texas) is
an electronic platform functioning as an image-based delineation
system, an image fusion software and a treatment planning tool.
It includes a digital atlas combining protocols and guidelines, clas-
sified according to tumor site and a vast library of normal tissue
structures. All protocols and information can be continuously
updated and customised. Interestingly, Anatom-e contains a
library of CTVs, including lymphatics at risk, prophylactic volumes
and OARs for most of the tumor sites and oncological scenarios, on
both intact and post-operative anatomy. The present study was set
in order to test the potential role of the platform Anatom-e in
reducing the intra- (Intra-OV) and inter-observer variability
(Inter-OV), within a multicentric context, in the delineation pro-
cess of prophylactic volumes in locally advanced rectal cancer
patients undergoing neoadjuvant RT. In particular, we tested the
efficacy of the platform in homogenizing the compliance of
different radiation oncologists (ROs) in following a pre-defined
delineation protocol.
Material and methods
This was a multicentric study implemented within the oncolog-
ical radiotherapy network of the Piedmont region in Italy and
endorsed by ‘Rete Oncologica del Piemonte e della Valle d’Aosta’.
The study was proposed to 14 centres belonging to the network
and 10 of them agreed to participate and were consequently
included. For each participating centre, a RO with a 5-yearipate, on a voluntary basis. Participating centers were provided
with the credentials to access the online version of Anatom-e,
which has most of the characteristics and tools of the physical plat-
forms (www.anatom.e.com). Two different clinical cases were cho-
sen to be delineated. Both of them were locally advanced rectal
cancer classified according to 2010 American Joint Committee on
Cancer/Union Internationale Contre le Cancer (AJCC/UICC) staging
system, undergoing neo-adjuvant long-course radiotherapy.
Patient 1 was a 59 years old male with a Stage IIIB (cT3N2aM0)
low lying rectal cancer with a mesorectal node in close proximity
to the mesorectal fascia. Patient 2 was a 49 years old female with
a Stage IIIC (cT4bN1bM0) rectal cancer located to the low rectum
with an anterior spread and infiltration of the posterior wall of
the vagina. Detailed characteristics of the 2 clinical cases can be
found in Fig. 1.
Target volume selection and delineation
For both cases, planning computed tomography (CT) images
were acquired from the second lumbar vertebra down to below
the lesser trochanters. All simulation images were acquired with
no contrast enhancement and had a 3 mm-slice thickness. Partici-
pating ROs were instructed to follow the atlas and the specific
instruction found in the Radiation Therapy Oncology Group (RTOG)
consensus published in 2009, during the delineation process [12].
Two consensus meetings comprising contouring laboratory were
organized before the start of the study to agree on the whole con-
touring workflow. In general, our study aimed at investigating
whether the compliance in following the indications of the RTOG
2009 consensus could be enhanced by the use of an advanced dig-
ital platform such as Anatom-e, compared to direct consultation of
the paper version of the aforementioned consensus. Participants
were asked to manually segment clinical target volumes (CTVs),
for both patient 1 and 2, on day 1 with and without the use of
the Anatom-e platform. After one week (day 2), the same ROs were
asked to contour again, with and without Anatom-e, the same CT
scans of the 2 patients. The treatment volumes to be contoured
and the corresponding nomenclature and description can be found
in Fig. 2. An example of the Anatom-e interface with the specific
ontology can be seen in Fig. 3.
Contour analysis
All volumes were imported in the Velocity platform (Varian
Medical Systems, Palo Alto, CA). To determine Intra-OV, we anal-
ysed and compared contours performed by the same RO on day 1
and day 2. To determine Inter-OV, we compared the contours
drawn by all different participants with a ‘ground truth’ contour
performed by an experienced RO dedicated to rectal cancer treat-
ment. The ‘ground truth’ contour was driven by the use of
Anatom-e and considered as the ‘gold standard’ for comparison.
An outline of all different contours obtained with or without the
platform can be found in Fig. 4. We decided to analyse overlap
between different contours using the Dice similarity coefficient
(DSC) which represents the ratio between the overlapping volume
and the encompassing volume, with the numerator multiplied
Fig. 1. Description of the 2 clinical cases.
Fig. 2. Anatom-e nomenclature of target volumes.
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overlap) [13]. To explore the distance between contours, we
employed the Hausdorff distance (HD), which is the maximum dis-
tance of each voxel of the reference set to the nearest point in the
comparison set [14]. We also calculated the mean distance to
agreement (MDA), which is the average distance that all outlying
points in the considered volume must be moved to achieve perfect
conformity-overlap with the reference volume [15]. For both HD
and MDA, lower values (in mm) correspond to a higher correspon-
dence between the compared volumes.
We investigated the overlap between contours performed on
day 1 and day 2 by the same operator for Intra-OV and between
all contours drawn by the ROs of all the 10 centres participating
in the present study and the ‘ground truth’ contour drawn in the
reference centre, for Inter-OV.
Statistical analysis
All the results were reported as the sample mean and standard
deviation (SD). Comparisons between groups were performed
using univariate t-Student test. Multiple subsets of data were anal-
ysed on a 8  8 grouping categorization. The difference between
multiple subsets of data was considered statistically significant if
t-Student test gives a significance level P (P value) less than 0.05.
The STATA software package (Stata Statistical Software: Release
13.1. Stata Corporation, College Station, TX, 2013) was used for
all statistical analysis.
Results
Detailed results can be found in Table 1. For the clinical case 1,
no significant difference was found in terms of Intra-OV (same RO;
day 1 vs day 2) for DSC, HD and MDA according to the use or not of
Anatom-e. In particular, the mean DSC was 0.95 (SD: ±0.43; range:
0.88–0.99) for day 1 vs day 2 without Anatom-e and 0.95 (SD:
±0.32; range: 0.91–0.10) (p = 0.71) with the use of the platform.
No difference was also found in terms of Inter-OV (different ROs;
day 1 vs ground-truth) for DSC, HD and MDA when using or not
Anatom-e. The mean DSC was 0.80 (SD: ±0.04; range: 0.76–0.86)
for day 1 vs ground-truth with no Anatom-e and 0.80 (SD: ±0.30;
range: 0.75–0.84) (p = 0.68) with the use of the system. For theclinical case 2, no significant difference was found in terms of
Intra-OV for DSC, HD and MDA according to the use or not of
Anatom-e. In particular, the mean DSC was 0.89 (SD: ±0.11; range:
0.62–0.99) for day 1 vs day 2 without Anatom-e and 0.91 (SD:
±0.77; range: 0.76–0.99) (p = 0.64) with the use of the platform.
A statistically significant difference was found in terms of Inter-
OV for DSC when using or not the platform. Mean DCS was 0.65
(SD: ±0.64; range: 0.58–0.79) for day 1 vs ground truth without
Anatom-e and 0.72 (SD: ±0.39; range: 0.67–0.77) (p = 0.03) with
the use of Anatom-e (Fig. 5a). With the use of Anatom-e, mean
MDA was lower with Anatom-e (3.61; SD: ±1.33; range: 2.85–
4.78) than without (4.14; SD: ±2.97; range: 2.18–5.21), with no
statistical significance (p = 0.21) (Fig. 5c). The use of Anatom-e
decreased the SD from 2.97 to 1.33 (Fig. 5b). Mean HD was lower
(26.06; SD: ±2.05; range: 24.08–32.62) but without statistical sig-
nificance (p = 0.14) compared to the one obtained without
Anatom-e (31.39; SD: ±1.31; range: 26.14–48.72).
Discussion
The current management of rectal cancer employs a multidisci-
plinary strategy which involves different professionals. Hence, it is
of crucial importance to verify the quality of the different treat-
ment strategies comprised within the combined modality
approach. For example, training, centre’s experience and the qual-
ity of total mesorectal excision have be shown to be prognostic fac-
tors in rectal cancer patients [16]. Moreover, a central review of
pathology report and an efficient feedback to surgeons has been
proven to improve the quality of the surgical procedure [17]. Also
RT, as a mainstay treatment option in the multimodality manage-
ment of cancer, needs quality assurance (QA) protocols to con-
stantly check for the quality of treatments (target volume
delineation, treatment plan optimization, dosimetric results and
delivery reliability) [11]. The contouring process of the target vol-
ume is a major source of uncertainty and error in RT and, since,
most of the times, this potential error remains constant during
the whole RT treatment, it may have a detectable impact on the
dose received by the tumor, especially for highly conformal tech-
niques, such as volumetric modulated arc therapy (VMAT) and
whenever image-guidance (with consequent CTV to PTV margin
reduction) is employed [18–20]. The factors that most consistently
Fig. 3. Visual example of the Anatom-e platform.
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bility, disagreement on target definition, extension and interpreta-
tion or lack of dedicated contouring protocols [18,21]. Inter-OV
during the delineation process is strongly affected by the imaging
modality and technique employed and by the specificity of the
observer (specialty, training and personal bias) [18]. This inter-
observer variation is detectable even during the delineation of vis-
ible and well-circumscribed targets such as in prostate cancer or
brain tumors with variation having an average factor of 1.3–2
[18,21]. It is, of course, much higher in body regions where
anatomical boundaries are not necessarily well-defined. The pelvis
is paradigmatic in this sense and rectal cancer RT volumes are a
good example [4]. Pelvic subsites such as the presacral space, the
mesorectum and the lateral lymphnodes are not trivial to be cor-
rectly defined on non-contrast-enhanced computed tomography
images [4].An even higher variation can be supposed in theevaluation of the extent of the microscopic involvement in the
delineation of the CTV. It has been shown that ROs tend to
delineate larger volumes compared to physician with different spe-
cialties [21]. Hence, standardization of the delineation process is of
paramount importance for all tumor sites, including rectal cancer.
As an example, in Belgium, the PROject on Cancer of the Rectum
(PROCARE) initiative was set to increase the use of guidelines
and quality indicators throughout the country, with decentralized
implementation of treatment protocols, prospective data registra-
tion and consequent feedback supply and benchmarking to
improve the homogeneity of CTV delineation in daily clinical prac-
tice [11]. Tools allowing for direct visualization of a specific con-
touring protocol are very useful to increase the consistency of
the delineation process. In this sense, the study performed by the
Radiation Committee of the Southwest Oncology Group (SWOG)
provided an important evidence on the effect of a consensus
Fig. 4. Delineated volumes for clinical case 2.
Table 1
Measures of intra- and inter-observer variability for both clinical cases.
Clinical case 1
Without Anatom-e With Anatom-e
Mean SD Range Mean SD Range p-value
Intraobserver variability (day 1 vs day 2)
DSC 0.95 0.43 0.88–0.99 0.95 0.32 0.91–0.10 0.71
MDA (mm) 0.90 0.76 0.14–2.07 0.77 0.62 0.04–1.71 0.70
HD (mm) 10.22 4.68 4.30–18.81 10.44 4.60 3.40–18.45 0.83
Interobserver variability (day 1 vs ground truth)
DSC 0.80 0.04 0.76–0.86 0.80 0.30 0.75–0-84 0.68
MDA (mm) 3.84 0.91 2.70–5.00 3.82 0.83 2.75–5.16 0.97
HD (mm) 28.91 3.18 23.18–33.49 30.67 3.53 26.11–35-71 0.31
Clinical case 2
Intraobserver variability (day 1 vs day 2)
DSC 0.89 0.11 0.62–0.99 0.91 0.77 0.76–0.99 0.64
MDA (mm) 1.26 1.14 0.49–3.70 1.22 1.15 0.94–3.58 0.94
HD (mm) 13.04 7.69 4.19–29.45 12.70 7.14 6.44–25.56 0.93
Interobserver variability (day 1 vs ground truth)
DSC 0.65 0.64 0.58–0.79 0.72 0.39 0.67–0.77 0.03
MDA (mm) 4.14 2.97 2.18–5.21 3.61 1.33 2.85–4.78 0.21
HD (mm) 31.39 1.31 26.14–48.72 26.06 2.05 24.08–32-62 0.14
Bold values represents results of particular interest.
SD; standard deviation; DSC: Dice similarity coefficient; MDA: mean distance to agreement; HD: Hausdorff distance; mm: millimeters.
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eation variability in rectal cancer [7]. Authors asked 13 physicians
and 1 reference expert to contour both gross tumor volume (GTV)
and CTV in a case of cT3N0M0 rectal cancer. The access to the
delineation atlas was provided or not on a random basis and obser-
ver variations were analysed on a volume basis with the conforma-
tion number [7]. The use of the aforementioned atlas resulted in a
significantly higher inter-observer agreement between physicians,
particularly for pelvic nodal regions [7]. Anatom-e (Anatom-e
Information Systems Ltd., Houston, Texas) is an electronic system
working as a platform able to drive delineation based on multi-
modality imaging, with an advanced image fusion software and
treatment planning characteristics. It includes a digital atlas builton the combination of more than 150 contouring atlases using 3
mm axial computed tomography (CT) and magnetic resonance
(MR) images acquired in treatment position, with more than
50.000 normal tissue structures available. It contains several treat-
ment protocols and guidelines, classified according to tumor site,
and allows for the personalization of institutional protocols. It
employs an evidence-based approach with a continuous update
of scientific information and literature, being connected online to
a central data server. Anatom-e contains a library of CTVs, includ-
ing lymphatics at risk, prophylactic volumes and OARs for most of
the tumor sites and oncological scenarios, on intact and post-
operative anatomy. The present study was aimed at investigating
whether the platform Anatom-e may increase the adherence to a
Fig. 5. Dice similarity coefficient, Hausdorff distance and mean distance to agreement with and without Anatom-e for clinical case 2.
38 P. Franco et al. / Clinical and Translational Radiation Oncology 11 (2018) 33–39specific protocol among different centres, with respect to CTV
delineation in rectal cancer patients planned to receive pre-
operative long-course RT. We chose to follow the RTOG 2009 con-
sensus guidelines since they were constitutively included in the
platform and most of the participating centres were familiar with
their indications. Patient 1 was a locally advanced low-lying rectal
cancer whose level of criticality lied on the proximity of a mesorec-
tal node to the mesorectal fascia. Patient 2 was again a locally
advanced low lying rectal cancer extending to the posterior wall
of the vagina. For patient 1, no differences in terms of DSC, HD
and MDA were found, when using or not the platform, on both
Intra-OV (same RO; day 1 vs day 2) and Inter-OV (different ROs;
day 1 vs ground-truth). The participants had a high degree of
self-consistency since the mean DSC was 0.95 for Intra-OV regard-
less of the use of the platform and the mean MDA was below 1 mm
even with no Anatom-e used. For Inter-OV, mean DSC was 0.80 and
mean MDA around 3.8 mm, independently of the platform. The
high consistency within and among ROs can be explained by the
low number in delineation variables in case 1, with very standard
prophylactic volumes to be included in the CTV (mesorectum, pre-
sacral space, bilateral internal iliac and obturator nodes) and a very
visible mesorectal node close to the mesorectal fascia to drive the
volume selection and definition. The other explanation might be
that most of the participants were trained in the same centre dur-
ing the residency program and hence they shared a common back-
ground knowledge and contouring approach. In clinical case 2, self-
consistency was again very high with a DSC around 0.9 regardless
of Anatom-e. Conversely, the inter-OV was significantly decreased
by the use of the Anatom-e platform. The DCS for day 1 vs ground
truth was significantly influenced by the use of Anatom-e (0.72 vs
0.65 without platform; p = 0.03), as an effect of a higher overlap of
all contours with the reference CTV. The mean MDA was lower
with the use of the platform (3.61 mm vs 4.14 mm; p = 0.21), but
with no statistical significance; the use of Anatom-e decreased
the SD from 2.97 to 1.33. That means that the mean distance
between the tested contours and the reference volumes were on
average lowered by the use of Anatom-e. At the same time the dis-
persion of the values around the mean values was lowered, as an
effect of the increase in homogeneity of the delineation process.
Clinical case 2 had a higher number of delineation variables com-
pared to case 1, with also bilateral external iliac and inguinal nodes
to be included in the CTV. Moreover, the involvement of the vagina
increased the complexity of the selection and delineation of treat-
ment volumes introducing a region of uncertainty represented by
the anterior aspect of the CTV. The anterior aspect of the nodal
regions within the pelvis is, in general, a source of potential dis-
agreement, because anatomical boundaries are less clear. More-
over, the infiltration of the posterior wall of the vagina pushed
ROs to extend anteriorly the CTV to cover the area of tumor spread,
but to a different extent depending on the contouring RO. The
visual evaluation of delineation variation according to pelvicsub-regions, confirmed the variability for the anterior border of
the CTV (cranially to the bladder) and for the anterior border of
the lateral lymphnodes, which is a critical boundary since no easily
recognizable landmarks are present at that level. This was one of
the reason for the increased Inter-OV, which was shown by the
lower DSC for case 2 compared to case 1 without the platform
(0.65 vs 0.80). This variability was mitigated by the use of the
Anatom-e platform which increased the DSC up to 0.72, lowered
the mean HD and decreased the SD for HD. This was evident also
by visual inspection of the anterior aspects of all contours
obtained, which had a higher overlap with the use of the system.
This is also in line with the data of Nijkamp et al., where the benefit
of the implementation of delineation guidelines based on adigital
atlas in rectal cancer patients was particularly observed in the
reduction of the disagreement among operators in the anterior
region of treatment volumes [22]. The increase of homogeneity
in the contouring process has been shown to have a dosimetric
impact on target coverage in rectal cancer patients undergoing
pre-operative RT [23]. This may have an influence on the quality
of the whole RT process and finally on patient’s outcome [24].
Improvement in interactive teaching for treatment volume delin-
eation is also a major need for education and training of profes-
sionals in radiation oncology (especially trainees and young
specialists) [25]. International professional societies such as ESTRO,
the European Society for Radiation Oncology, developed an educa-
tional project denominated as FALCON (Fellowship in Anatomic
deLineation and CONtouring) to increase the homogeneity in the
delineation process, comparing individual contours with endorsed
guidelines or expert opinions [26]. This initiative, based on short
and interactive workshops, was shown to be effective in reducing
Inter-OV in specific clinical contexts [27].Conclusion
The use of a digital platform such as Anatom-e decreased the
inter-observer variability among operators in the delineation pro-
cess of CTV for locally advanced rectal cancer patients with a com-
plex disease presentation planned to receive neoadjuvant RT. This
system may be helpful in increasing the compliance to follow
shared guidelines and protocols, potentially reducing discrepancies
and discordances in delineated treatment volumes.Declarations
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